More M&A Deals Could Boost Biotech ETFs

By
Devon Layne
December 12, 2012
Share:

 

Amgen’s $415 million acquisition of DeCode suggests big-pharma will transition from blockbuster drugs to specialized medicines that target specific areas of the human body, a possibility that could bode well for the biotech sector and its ETFs, according to an article on ETF Trends.

The pursuit for targeted drugs could also benefit from the Obama administration’s push toward health care reform, as the extra insurance coverage would boost demand for medicines, the article said.

For investors seeking a doorway into biotech investments, consider these sector-covering ETFs as a starting point:

  • Market Vectors Biotech ETF (NYSEArca: BBH)
  • iShares Nasdaq Biotechnology ETF (NYSEArca: IBB)
  • First Trust NYSE Arca Biotechnology Index Fund (NYSEArca: FBT)

 

Head over to ETFtrends.com to learn more about ETFs within the biotech sector.

ETF DAILY DATA

The small-cap fund 'IWM' added money on Thursday, Jan. 22, as net inflows and markets stoked higher by eurozone QE news lifted total U.S.-listed ETF assets above $2 trillion.

A slew of iShares funds, including the eurozone-focused 'EZU,' paced the firm's issuer-leading inflows on Thursday, Jan. 22. The ECB's announcement about aggressive QE in the eurozone stoked markets and lifted total U.S.-listed ETF assets to more than $2 trillion.

ETF.COM ANALYST BLOGS

By Dave Nadig

Sometimes it’s what’s under the hood that matters. Sometimes it’s not.

By Dave Nadig

President Obama may be undermining the benefits of tax-loss harvesting.

By Scott Burley

Wouldn’t it be nice to know if your favorite ETF were part of a securities-lending program?

By Dave Nadig

Long term, the floating Swiss franc is good for you.